<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035394</url>
  </required_header>
  <id_info>
    <org_study_id>2021-02970</org_study_id>
    <nct_id>NCT05035394</nct_id>
  </id_info>
  <brief_title>Swedish Microinvasive Glaucoma Surgery Study (SMIGS)</brief_title>
  <acronym>SMIGS</acronym>
  <official_title>A Prospective Randomized Trial Comparing Cataract Surgery as Stand Alone and Cataract Surgery Combined With Kahook Dual Blade Glide Goniotomy or Istent Inject W Trabecular Micro-Bypass Stent in Open-Angle Glaucoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the efficacy of Cataract Surgery as stand-alone&#xD;
      compared to Cataract Surgery in combination with Kahook Dual Blade Glide goniotomy (KDB) or&#xD;
      iStent Inject W Trabecular Microbypass Stent (Istent) in eyes with Open-angle glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma patients with significant cataract are being informed about the study and potential&#xD;
      risks, all participants giving written informed consent and meeting the criteria will become&#xD;
      eligibility for study entry. Participants meeting the eligible requirements will be&#xD;
      randomized to Cataract Surgery as stand-alone (40 patients) or Cataract Surgery combined with&#xD;
      Kahook Dual Blade Glide (40 patients) or iStent Inject W (40 patients).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">September 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of intraocular pressure lowering medications compared to baseline</measure>
    <time_frame>12 to 24 months</time_frame>
    <description>Accountability of intraocular pressure lowering medications used by the patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with ≥20 percent intraocular pressure reduction or reduction with ≥1 medication compared to baseline</measure>
    <time_frame>12 to 24 months</time_frame>
    <description>Intraocular pressure measured by Goldmann applanation tonometry (GAT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with intraocular pressure ≤21 mm Hg, ≤18 mm Hg, ≤15 mm Hg and ≤12mm Hg</measure>
    <time_frame>12 to 24 months</time_frame>
    <description>Intraocular pressure measured by Goldmann applanation tonometry (GAT)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants that need further surgery</measure>
    <time_frame>12 to 24 months</time_frame>
    <description>Arm comparison of future need for microinvasive surgery, filtering surgery or cyclodestructive laser</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants that need additional medical therapy</measure>
    <time_frame>12 to 24 months</time_frame>
    <description>Assessment of the need for future medical therapy in the study groups</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Cataract</condition>
  <condition>Kahook Dual Blade Glide</condition>
  <condition>Istent Inject W</condition>
  <condition>MIGS</condition>
  <condition>Goniotomy</condition>
  <arm_group>
    <arm_group_label>Cataract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cataract surgery as stand alone. Cataract surgery will be performed in a standardized fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KDB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cataract surgery combined with Kahook Dual Blade Glide goniotomy. The goniotomy will be performed at the end of cataract surgery through the temporal cataract incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Istent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cataract surgery combined with iStent Inject W. The two stents will be injected in Schlemms canal at the end of cataract surgery through the temporal cataract incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>Cataract Surgery in a standardized fashion</description>
    <arm_group_label>Cataract</arm_group_label>
    <other_name>Phacoemulsification</other_name>
    <other_name>Cataract Surgery as stand-alone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>KDB</intervention_name>
    <description>Goniotomy with KDB glide will be performed at the end of Cataract Surgery</description>
    <arm_group_label>KDB</arm_group_label>
    <other_name>Kahook Dual Blade Glide, New World Medical, Inc, Rancho Cucamonga, CA</other_name>
    <other_name>KDB glide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Istent</intervention_name>
    <description>Two iStent inject W will be injected into Schlemms Canal at the end of Cataract Surgery</description>
    <arm_group_label>Istent</arm_group_label>
    <other_name>iStent inject W</other_name>
    <other_name>Trabecular Micro-Bypass Stent System Model G2-W, Glaukos Corporation, San Clemente, California</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Only one eye per participant&#xD;
&#xD;
          -  Clinically significant cataract&#xD;
&#xD;
          -  Glaucoma or intraocular hypertension treated with one to four medications and no need&#xD;
             for filtering glaucoma surgery at the time of study enrollment.&#xD;
&#xD;
          -  Open chamber angle with Schaffer grading three to four in at least two quadrants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous glaucoma surgery, including cyclodestructive procedures.&#xD;
&#xD;
          -  Selective Laser Trabeculoplasty (SLT) within 90 days prior to planned surgery.&#xD;
&#xD;
          -  Exudative age-related macular degeneration, proliferative diabetic retinopathy,&#xD;
             clinically significant corneal dystrophy, other eye disease that affect intraocular&#xD;
             eye pressure or visual field.&#xD;
&#xD;
          -  Unable to participate and make written consent due to another medical condition.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Barkander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of Ostersund, department of Ophtalmology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Barkander, MD</last_name>
    <phone>0730277070</phone>
    <phone_ext>+46</phone_ext>
    <email>anna.barkander@regionjh.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gauti Johannesson, MD, PhD</last_name>
    <phone>070-2200798</phone>
    <phone_ext>+46</phone_ext>
    <email>gauti.johannesson@umu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eye clinic at the hospital of Ostersund</name>
      <address>
        <city>Ostersund</city>
        <state>Östersund</state>
        <zip>83183</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Barkander</last_name>
      <phone>+46730277070</phone>
      <email>anna.barkander@regionjh.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Umeå University</investigator_affiliation>
    <investigator_full_name>Anna Barkander</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

